Biotech News
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
investor.roivant.com2026-05-06 14:44 EST
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. Brepocitinib 30 mg demonstrated clinically meaningful and statistically